ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2019) 63 P1162 | DOI: 10.1530/endoabs.63.P1162

Microvascular blood flow measurements of the thyroid nodules by diffuse optics

Gloria Aranda Velazquez1, Giuseppe Lo Presti2, Davide Contini3, Lorenzo Cortese2, Alberto Dalla Mora3, Sixte de Fraguier4, Irene Halperin1, Felicia Alexandra Hanzu1, Antonio Pifferi3, Bogdan Rosinski5, Sanathana Sekar3, Mattia Squarcia1, Paola Taroni3, Alberto Tosi3, Udo M Weigel6, Turgut Durduran7 & Mireia Mora1


1IDIBAPS, Fundació Clínic per la Recerca Biomèdica, Barcelona, Spain; 2ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Castelldefels (Barcelona), Castelldefels, Spain; 3Politecnico di Milano-Dipartimento di Fisica, Milan, Italy; 4ECM - ECHO CONTROL MEDICAL, S.A.S, Angoulême, France; 5VERMON S.A., Tours, France; 6HemoPhotonics S.L., Castelldefels, Spain; 7ICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science and Technology, Castelldefels (Barcelona), Barcelona, Spain.


Background: The most common tool to test malignancy in the study of thyroid nodules (TN) is ultrasound and fine needle aspiration biopsy (FNAB). However, the sensitivity and specificity of the methods and the effectiveness in thyroid cancer are limited; therefore new methods to study thyroid nodules are required. In this way our goal is to introduce hybrid diffuse optical instruments that are capable to measure and discriminate altered microvascular blood flow, blood volume and tissue scattering coefficients of TN. Near-infrared diffuse optical technologies aim to overcome the shortcomings of present techniques while screening for malignant thyroid nodules for early and fast diagnosis of cancer. This idea was based on the previous experience in breast cancers with diffuse optical techniques.

Methods: We have developed a device based on near-infrared diffuse correlation spectroscopy (DCS), which is a technology aimed at retrieving the microvascular flow of a certain region of tissue by mean of low power near-infrared laser light, and used in combination with a commercial ultrasound system (US). In order to combine these devices, we have developed a probe enabling multimodal data acquisition and subsequently we have analyzed the optical properties and the blood flow index in the thyroid lobes of eleven subjects who presented a thyroid nodule.

Results: Four subjects have required FNAB: P4 and P7 were reported as being malignant (Bethesda VI and IV respectively) while P6 and P8 were evaluated as being benign (Bethesda II). Surgical removal confirmed papillary thyroid carcinoma in P4, while denied the result of FNAB for P7 (Multinodular thyroid hyperplasia). We have considered the contralateral lobe as intra-subject reference to validate the feasibility of the DCS system in a very absorbing tissue as thyroid is. The difference between the blood flow index of the nodule and the contralateral lobe is maximum for subject P4, while the difference in benign subjects is lower. T-test showed no significant difference between benign nodules and contralateral lobes. Subject P7 showed a small difference as for other benign subjects despite the FNAB results indicating presence of malignancy.

Conclusion: Apparently diffuse optics technologies would be able to differentiate malignant thyroid nodules from benign thyroid nodules, but more measurements require confirming our preliminary results as that diffuse optical technology can complement the current techniques such as US and FNAB. A new measurement campaign is being scheduled with a completed, fully integrated device that was developed within the LUCA project (http://www.luca-project.eu).